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Objective: The aim of this study was to identify the demographic features and in-hospital preva-
lence of myocarditis in patients undergoing transarterial endomyocardial biopsy (EMB) for unex-
plained cardiomyopathy.
Patients and methods: This was a prospective observational study. We recruited all patients with
unexplained cardiomyopathy presented at Assiut University Hospital from January 2014 till
December 2014. The inclusion criteria were namely acute symptoms of heart failure, worsening
of ejection fraction (EF) despite optimized therapy, hemodynamically signiﬁcant arrhythmias, heart
failure with concurrent rash, fever, or peripheral eosinophilia and new-onset cardiomyopathy in the
presence of known amyloidosis. We excluded patients with uncontrolled hypertension, diabetes
mellitus, ischemic, congenital, rheumatic heart disease, peripartum cardiomyopathy, cardiotoxic
exposure, alcoholic and familial cardiomyopathies. All patients were subjected to full examination
with ECG, echocardiography and coronary angiography, and then 3 EMB samples via femoral
artery were taken from the LV. The histopathological examination of all biopsies was done.
Results: Out of the 1100 patients admitted to our department, 15 patients (1.4%), who had unex-
plained cardiomyopathy were included in our study. Seventy-three percent were males with mean
age 37.8 ± 17 y. 87% were from rural areas, and 73.3% presented with dyspnea grade III to IV
for a duration period that varied from 2 to 8 weeks. 33% had an EF > 40%. 33 EMB samples from
11 patients were examined. 7 out of 11 patients (63.6%) proved to have myocarditis on pathological
examination, 5 of them had active myocarditis, 1 had chronic myocarditis and 1 had borderline
myocarditis. Three patients (27.3%) had no pathological evidence of inﬂammation and one patientl biopsy
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for unexplained cardiomyopathy, The Egypt(9.1%) had cardiac amyloidosis. Four out of 15 patients (26.7%) did not undergo EMB because of
LV thrombus or bleeding tendency. None of our patients had any complication from EMB.
Conclusion: The in-hospital prevalence of myocarditis is high among patients with unexplained car-
diomyopathy. EMB via femoral artery is safe and essential in conﬁrming the diagnosis.
 2016 Egyptian Society of Cardiology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Myocarditis is clinically and pathologically deﬁned as ‘‘inﬂam-
mation of the myocardium”. The true incidence of the disease
is unknown due to a great variation in clinical manifestations
from asymptomatic changes on electrocardiogram to fulmi-
nant heart failure, arrhythmias and sudden cardiac death [1].
The diagnosis of myocarditis is still a challenge, due to the
non-speciﬁc pattern of clinical presentation and the lack of
standardized diagnostic algorithm [2]. Cardiac magnetic reso-
nance (CMR) is the ideal technique to detect soft tissue
changes such as edema and inﬂammation [3,4]. However,
imaging techniques such as CMR or echocardiography can
only provide non-invasive tissue characterization but fail in
revealing the true underlying causes that determine prognosis
and treatment of the disease. Invasive removal of a sufﬁcient
number of tissue samples by endomyocardial biopsy (EMB)
is always necessary when an exact diagnosis is needed [5–8].
EMB is an invasive, nonsurgical diagnostic technique, which
makes it possible to obtain histological samples of myocardial
tissue through the use of biopsy forceps [9]. Cardiac biopsy
was initially performed in the 1950s by means of limited thora-
cotomy [10–14]. The role of EMB in the diagnosis and treat-
ment of cardiovascular diseases is still controversial.
However, EMB is the gold standard for heart disease when
the common non-invasive methods do not make precise
histopathological diagnosis possible [15–19]. EMB samples
can be taken from the right or left ventricle, via the venous
or arterial route [20]. EMB may be guided by ﬂuoroscopy,
2-D echocardiography, or both [9,21,22]. However, ﬂuo-
roscopy alone is the most common method used [23].
Also, because of the lack of available facilities and clinical
experience, EMB appears to be infrequently used to diagnose
myocarditis [20,22,23]. Reported complications range from
minor site hematoma, to right ventricular perforation; and
were reported in less than 1% of patients [24].
The aim of this study was to identify the demographic fea-
tures and in-hospital prevalence of myocarditis in patients
undergoing transarterial endomyocardial biopsy (EMB) for
unexplained cardiomyopathy.
2. Methods
2.1. Study group and design
We performed a prospective observational study. From
January 2014 to December 2014, 1100 patients who were
admitted to the cardiology department at Assiut University
Hospital complaining of dyspnea on exertion or chest pain
were assessed for eligibility. Fifteen patients with unexplainedM et al. Demographic features and preva
Heart J (2016), http://dx.doi.org/10.10cardiomyopathy were included. The inclusion criteria were as
follows: acute symptoms of heart failure refractory to standard
management, substantial worsening of EF despite optimized
pharmacological therapy, development of hemodynamically
signiﬁcant arrhythmias, particularly progressive heart block
and ventricular tachycardia, heart failure with concurrent rash,
fever, or peripheral eosinophilia, new-onset cardiomyopathy in
the presence of known amyloidosis, sarcoidosis, or hemochro-
matosis. The exclusion criteria were patients with a history of
ischemic heart disease, uncontrolled hypertension, diabetes,
congenital or rheumatic heart disease, patients with familial
cardiomyopathy, peripartum cardiomyopathy, patients with
cardiotoxic exposure and alcoholic patients [25]. The trial pro-
tocol was reviewed and approved by the institutional review
committee, and all patients granted their informed consent
to be included in the trial. The demographic and clinical data
were collected using a standardized ‘‘procedural datasheet”.
2.2. Patients diagnosis protocol
All patients were subjected to full history taking to identify the
most common symptoms of myocarditis such as chest pain,
breathlessness, fatigue, palpitations and fainting attacks. The
history of ﬂu-like symptoms (a cough, fever, malaise) and med-
ications was used. Then this was followed by full physical
examination and 12 lead electrocardiogram (ECG). All
patients had detailed echocardiography (ECHO) study by an
independent operator to analyze the suspected etiology of
heart failure symptoms. It was only after ECHO assessment
that patients were included into the study as unexplained
cardiomyopathy.
2.3. Cardiac catheterization
Coronary angiography (CA) was carried out on all included
patients to exclude coronary artery disease before doing the
EMB. CA was performed using the femoral approach in all
our patients with 6 F catheters through the common femoral
artery according to standard guidelines [26].
2.4. Endomyocardial biopsy (EMB)
EMB was taken from the left ventricle (LV). 6 French femoral
artery sheaths were inserted into the left or the right femoral
artery. Judkins right (JR) 3.5 guiding catheter was introduced
via the femoral sheath into the LV. A Cook Flexible Biopsy
forceps (with a standard cup for tissue sampling of 5.2 Fr vol-
ume 2.25 mm3) were used to take EMB. At least 3 samples of
biopsy from the interventricular septum, apex and lateral wall
of the LV were taken under ﬂuoroscopic guidance in rightlence of myocarditis in patients undergoing transarterial endomyocardial biopsy
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2500 IU of heparin was given in the sheath at the beginning
of CA in all patients. At the end of EMB, mandatory 2D echo
assessment was done for all patients for the exclusion of any
complications. The main reported complications were pericar-
dial effusion or new onset mitral incompetence due to chordal
involvement.
2.5. Histopathological analysis
From each patient, 3 endomyocardial biopsies were taken
into 3 separate bottles containing 10 mL of 10% formalin
and were referred to a specialist in cardiac pathology for ﬁx-
ation and further assessment [9,27,28]. Tissue specimens were
processed and 5 lm sections were cut and stained with hema-
toxylin and eosin or other speciﬁc stains according to each
case. Sections were examined by light microscopy and the
following features were evaluated: these were the presence
of inﬂammatory cells, number, and distribution of inﬂamma-
tory cells, the presence of necrosis or ﬁbrosis. The conﬁrmed
diagnosis of myocarditis was according to the Dallas criteria
[29].
2.6. Study end points
Our study aimed to identify the in-hospital prevalence of unex-
plained cardiomyopathy among all patients presented with
dyspnea or chest pain, and it also had the purpose of elucidat-
ing the rate of conﬁrmed myocarditis among these patients and
its subtypes by the histopathological analysis of EMB. The
analysis of the safety of EMB from the LV using the femoral
artery sheath was another end point of the study.Table 1 Patients’ demographic criteria.
Variable Unexplained CM N= 1
Age (years) 37.8 ± 17.7
Male gender n (%) 11 (73.3%)
Geographical distribution
Rural 13 (86.6%)
Urban 2 (13.3%)
Hypertension n (%) 0
Diabetes mellitus n (%) 0
Hepatitis C infection n (%) 1 (6.6%)
Smoking n (%) 5 (33%)
Known ischemic heart, n (%) 0
Dyslipidemia, n (%) 4 (26%)
Systolic BP (mmHg) 122 ± 62
Diastolic BP (mmHg) 76 ± 26
Pulse (bpm) 99 ± 26
Weight (kg) 80 + 17
Height (m) 166 ± 7
Hemoglobin (mg/dl) 11 + 3
Platelets (u/L) 273 + 77
INR impaired n (%) 2 (13%)
Chronic Diuretics therapy 4 (26%)
Chronic ACEI or ARB therapy 4 (26%)
Chronic BB therapy 2 (13%)
Data are presented as mean ± standard deviation, number (%) of patient
receptor blocker; BB, Beta blockers; CM, cardiomyopathy.
Please cite this article in press as: Hassan AKM et al. Demographic features and preva
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Categorical data were presented as counts and proportions
(percentages). The normal distribution of continuous data
was tested using a Kolmogorov–Smirnov test. Continuous
and normally distributed data are presented as mean ±1 stan-
dard deviation. These comparisons were performed using the
SPSS version 16.0 software package (SPSS Inc., Chicago,
IL), and a p-value of 60.05 was considered to be signiﬁcant.
3. Results
3.1. Patients’ characteristics
The baseline demographic and clinical characteristics of the
study group are summarized in Table 1. Fifteen patients with
unexplained CM were signiﬁcantly younger compared to other
screened patients and 73.3% of them were males. One patient
was known to have hepatitis C, and 86.6% were from rural
areas. Clinical examination of admission and history of previ-
ous drugs were not signiﬁcantly different between those with
suspected unexplained CM and other screened patients except
for age (Table 1). The younger patients were presented in the
unexplained CM group with less use of diuretic treatment com-
pared with other screened patients. None of our patients had
signiﬁcant eosinophilia in their blood picture analysis.
3.2. Symptoms, ECG and ECHO findings
The baseline clinical presentation of the included patients with
ECG and ECHO ﬁndings is summarized in Table 2. Most of
the patients presented with dyspnea grade III to IV, varied5 Patients screened N= 1085 p
60.9 ± 10.7 0.002
801 (73%) NS
NS
868 (80%)
217 (20%)
499 (46%) –
401 (37%) –
217 (20%) 0.02
509 (47%) NS
358 (33%) –
325 (30%) NS
134 ± 30 NS
80 ± 14 NS
88 ± 14 NS
77 ± 12 NS
164 ± 7 NS
12 ± 2 NS
261 ± 66 NS
217 (20%) NS
499 (46%) 0.01
358 (33%) NS
217 (20%) NS
s, ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin
lence of myocarditis in patients undergoing transarterial endomyocardial biopsy
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Table 2 Complaint and electrocardiographic and echocardio-
graphic ﬁndings in the study patients.
Variables Unexplained CM, N (%)
Clinical presentation
Attacks of palpitations 1 (6.7)
Chest pain 2 (13.3)
Dyspnea 11 (73.3)
Orthostatic hypotension 1 (6.7)
ECG changes
Sinus rhythm 14 (93.3)
Atrial ﬁbrillation 1 (6.7)
Normal axis 9 (60)
Left axis deviation 6 (40)
Diﬀusely Inverted T wave 4 (26.7)
Normal QRS duration 11 (73)
LBBB 4 (27)
ECHO analysis
EF 6 40% 10 (67)
EF > 40% 5 (33)
Normal chamber dimensions 2 (13)
Dilated all chambers 9 (60)
Dilated atria only 1 (7)
Concentric LVH 2 (13)
Dilated LV 1 (7)
EF, Ejection fraction; CM, Cardiomyopathy; LBBB, Left bundle
branch block; LV, left ventricle.
4 A.K.M. Hassan et al.for a duration from 2 to 8 weeks (73%) and sinus tachycardia
(93%). A normal ECG axis between 30 and +90 was present
in 60% of patients. Through the means of detailed ECHO
assessment, we found 10 patients (66.7%) had a picture of
dilated cardiomyopathy (DCM) with an ejection fraction
(EF) 640% and global hypokinesia. On the other hand, 5
patients (33.3%) had EF > 40% with normal wall motion, 2
of them had normal dimensions, another 2 had concentric
LVH and one patient had dilated the atria (Table 2).Figure 1 Distribution of patien
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The results of pathological examination of the 33 EMB sam-
ples are summarized in Fig. 1. Seven patients proved to be
myocarditis according to the Dallas criteria [29]. Five of them
had active myocarditis showing inﬁltration with inﬂammatory
cells (polymorphs and lymphocytes) and focal necrosis of car-
diomyocytes. The remaining 2 patients had borderline
myocarditis where no necrosis was present in cardiomyocytes
but there was inﬁltration with inﬂammatory cells as presented
in Fig. 2. Three patients had no pathology detected and were
considered negative for myocarditis, and one patient had car-
diac amyloidosis with amyloid deposition identiﬁed by Congo
red stain (Fig. 2). 10 patients included in the study had DCM,
by EMB, 4 of them (40%) were found to have myocarditis.
Four patients did not undergo biopsy because of con-
traindications to the maneuver, 2 had LV thrombus and 2
had a bleeding tendency with INR> 3.
4. Discussion
The main ﬁnding in our study was as follows:
1. The in-hospital prevalence of unexplained CM was 1.4%
and myocarditis was 0.63%.
2. Myocarditis proved by pathological examination of EMB
represents 64% of these patients.
3. EMB from the LV using Cook bioptomes via transfemoral
artery sheath is safe and essential in conﬁrming the
diagnosis.
With all modesty, to the best of our knowledge, this is the
ﬁrst report on the use of transarterial EMB for the diagnosis of
myocarditis in Upper Egypt. EMB is mandatory in suspected
myocarditis of unknown etiology [9]. According to the Dallas
criteria [29], acute myocarditis is deﬁned by lymphocytic inﬁl-
trates in association with cardiomyocyte necrosis. Borderline
myocarditis is characterized by inﬂammatory inﬁltratest according to biopsy result.
lence of myocarditis in patients undergoing transarterial endomyocardial biopsy
16/j.ehj.2016.09.005
Figure 2 (a) Acute myocarditis showing diffuse inﬁltrate by mixture of polymorphs and lymphocytes (arrows) with cardiomyocyte
necrosis. (b) Cardiac amyloidosis showing homogenous structureless pink material (amyloid) in between cardiac muscles. (c) Borderline
myocarditis: demonstrating few inﬂammatory cells without cardiomyocytes necrosis. (d) EMB showing the absence of inﬂammation or
necrosis and diagnosed as negative for myocarditis (H&Ex400).
Demographic features and prevalence of myocarditis in patients 5without evidence of cardiomyocyte necrosis. Limitations of
Dallas criteria are high inter-observer variability in interpret-
ing biopsy (especially borderline myocarditis) [29]. EMB is
considered to be positive for inﬂammation by immune-
histochemical detection of focal or diffuse mononuclear inﬁl-
trates with >14 cells/mm2, in addition to enhanced expression
of HLA class II molecules [7].
None of our patients had any reported complication after
doing EMB in accordance with Karjalainen and Heikkila [30].
The actual prevalence of myocarditis is unknown in our
locality, in accordance with previous reports because the infre-
quency of the disease requires a large study population and the
patient will have to be examined during the early course of the
disease leading to wide variation in the results found [31]. Dur-
ing our study that took one year from the beginning to the end
of 2014, 15 patients were diagnosed as unexplained cardiomy-
opathy and suspected to have myocarditis due to their clinical
presentation out of 1100 patients admitted to cardiology
department complaining of dyspnea or chest pain. Only 7 of
these patients were diagnosed to have myocarditis by EMB
within hospital prevalence of myocarditis 0.63%. This number
is a bit higher compared to a study done by Karjalainen and
Heikkila [30] which included 672 Finnish soldiers in Central
Military Hospital in Helsinki over a 20 year period. All cases
with suspected heart disease (chest symptoms, changes in
ECGs, detection of markers of myocardial injury in serum,
DCM of recent onset) in the hospital were subjected toPlease cite this article in press as: Hassan AKM et al. Demographic features and preva
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diagnosed myocarditis by EMB within hospital prevalence
0.014%. Another study was done in China in nine hospitals
by Lv et al. [32] on 1709 patients in a 3 year period, and the
prevalence rate was found to be 0.041%. The difference in
the prevalence rates can be explained by the small number of
our studies.
In our study only 7 out of 15 patients (46.6%) were posi-
tively diagnosed as having myocarditis by pathological exam-
ination, and this is in agreement with Yilmaz et al. [20] who
had a 2-center study on 755 patients with clinically suspected
myocarditis. Myocarditis was the most frequent diagnosis in
the study group and was found in 329 (43.6%) of patients. It
is also in agreement with Kasner et al. [33] who had a study
on 43 patients with clinically suspected myocarditis, and 14
(41.2%) of the patients were found to have active myocarditis.
On the other hand, Gilotra et al. [34] studied 236 patients who
presented with acute unexplained HF during the period from
2000 to 2009 and had undergone EMB, and 48 (20.3%) of sus-
pected patients were found to have myocarditis in the biopsy.
Also Mavrogeni et al. [3] studied 20 patients with clinically sus-
pected myocarditis. He found only 25% of patients had proven
myocarditis by EMB. It is also published in a review article by
Veinot [35] that in cases of clinically suspected myocarditis,
only 17–29% are biopsy conﬁrmed.
Results of EMB are usually affected by two opponents, and
the 1st opponent is the fading of inﬁltration of inﬂammatorylence of myocarditis in patients undergoing transarterial endomyocardial biopsy
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opponent is sampling errors [36]. These aforementioned fac-
tors made us to adopt the methodology in this study by taking
the biopsies during the early stage of the disease and taking
biopsies from different areas of LV which may help to get
higher results.
In the present study, 10 of the 15 patients (66.6%) had the
picture of dilated cardiomyopathy with EF > 40%, and
myocarditis was found in 4 patients (40%) of them. This is in
agreement with Towbin et al. [37], who had a study on 1426
patients diagnosed as having DCM, 89 centers shared in this
study in North America during the period from 1990 to 2003,
primary DCM was determined by strict criteria, and patients
with disease due to immunologic, endocrine, drug toxicity or
any other cause were excluded. The most common cause, they
found for DCM by EMB was myocarditis in 46% of patients.
However, Tian et al. [36] found in a study on 53 patients that
suffered from unexplained cardiomyopathy during the period
from 2006 to 2009, 19 of the said patients were diagnosed as
DCM by echocardiography, all the patients underwent EMB
and 5 (26.3%) of the 19 were found to have myocarditis by
biopsy. Also, the consensus statement on EMB from the asso-
ciation for European Cardiovascular Pathology and the Society
for Cardiovascular Pathology, stated that myocarditis is found
in about 10% of cases of clinical DCM [1].
This study had several limitations, among which were the
small number of biopsy samples, the absence of ECG and
ECHO data for all screened patients, and the lack of follow-
up. One other shortcoming of this study was the lack of
immune histochemical analysis of biopsy samples and molecu-
lar analysis with DNA-RNA extraction and RI-PCR ampliﬁ-
cation of the viral genome to rule in/out viral etiology was
not performed. However, this is our ﬁrst report and our main
concern was to develop the system to implement EMB sam-
pling technique and set in motion the process of the preserva-
tion of samples and the onward collaboration with a specialist
in the pathology department to handle and study all cardiac
specimens in this early report of our continuing project on
unexplained CM patients.
5. Conclusion
The in-hospital prevalence of myocarditis is high among
patients with unexplained cardiomyopathy. EMB via femoral
artery is safe and essential in conﬁrming the diagnosis.
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